Provectus Pharmaceuticals has announced that the first breast cancer patient
has completed treatment in the company's Phase I trial of PV-10 (also known
as Provecta). The trial is designed to evaluate the safety and preliminary efficacy
of PV-10 in five patients with recurrent breast carcinoma. Each patient enrolled
in the study is having PV-10 injected into one or more tumors, which are observed
for a period of one to three weeks thereafter. The patients then undergo standard
surgery to remove their tumors, allowing thorough assessment of the effects
of PV-10 in breast cancer tissue and surrounding normal tissue.
PV-10 is an agent that is retained in tumor cells while leaving normal tissue unharmed, thereby killing the tumor and sparing healthy tissue. Preliminary response data from metastatic melanoma patients undergoing similar treatment with PV-10 have been comparable to that observed in preclinical studies of melanoma, breast carcinoma and liver cancer.